Golvatinib

Gastric Cancer

Eisai Inc.Small moleculePhase 1/2Dormant

CC

42/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 35/ 100
Competitive Position: 65/ 100

Competitive context

283 Active assets in the Gastric Cancer cohort.

Asset / Sponsor	Phase	Rating
Rivoceranib Jiangsu Hansoh Pharmaceutical Co., Ltd.	Phase 4	BBB
FLUOROURACILUM I-Mab Biopharma US Limited	Phase 4	BB
Eloxatin Qilu Pharmaceutical Co., Ltd.	Phase 3	BB
Pembrolizumab Eikon Therapeutics	Phase 3	BB
Epirubicin Rondo Therapeutics	Phase 3	BB

View all 50 →

Same molecule, other indications

Golvatinib is also rated in:

cancerDormant

CC

Indicative ·

41 / 100

Advanced or Metastatic Solid TumorsDormant

CC

Indicative ·

40 / 100

neoplasmDormant

C

Indicative ·

38 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.